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Abstract The aim of the present study was to investigate
boneformation torecombinant humanbonemorphogenetic
protein-2 (rhBMP-2)-biocoated and rhBMP-2-nonbio-
coated titanium implants after implantation in dogs.
Implantation of sand-blasted and acid-etched (C), chromo-
sulfuric acid surface-enhanced (CSA), and rhBMP-2-
biocoated CSA [BMP-A: noncovalently immobilized
rhBMP-2 (596 ng/cm
2), BMP-B: covalently immobilized
rhBMP-2 (819 ng/cm
2)] implants was performed in both
themandibleandtibiaofdogs.After4weeksofhealing,the
percentage of direct bone to implant contact (BIC) and the
induced bone density (BD) at a distance of less than and
greater than 1 mm adjacent to each implant was assessed.
Histomorphometric analysis of implants inserted in the
mandible and tibia revealed that BIC values appeared to be
highest in the BMP-B group, followed by BMP-A, CSA,
and C. BD as measured at a distance of <1 mm revealed
obvious differences between groups: BMP-B>BMP-
A>CSA>C. However, no differences between groups
were observed at a distance of >1 mm. Within the limits
of the present study, it may be concluded that rhBMP-2
immobilized by covalent and noncovalent methods on
CSA-treated implant surfaces seemed to be stable and
promoted direct bone apposition in a concentration-
dependant manner.
Keywords rhBMP-2 . Titanium implant . Bioactive
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Introduction
The adhesion of plasma proteins on the surface of titanium
implants has been reported to play an essential role in the
process of osseointegration [2, 4, 8, 9]. Each surface of a
material is characterized by a unique composition of
adsorbed proteins, which influences the type of cells that
may adhere. Subsequently, the specific pattern of adsorbed
proteins determines the type of tissue that will develop at
the interface between the implanted material and the host
[32, 41, 42]. In recent years, several modifications of
specific surface properties such as structure, chemistry,
surface charge, and wettability have been investigated to
improve osseointegration of titanium implants [1]. Addi-
tionally, several growth factors and cytokines have also
been suggested to stimulate a deposition of cells with the
capacity of regenerating the desired tissue [27, 39, 46]. In
case of endosseous titanium implants, an enhanced prolif-
eration and differentiation of undifferentiated mesenchy-
mal cells, osteoprogenitor cells, and preosteoblasts into
osteoblasts may improve bone response and subsequently
osseointegration [5]. One particular growth factor, bone
morphogenetic protein (BMP), has shown considerable
potential to stimulate bone formation both in extraskeletal
sites [47, 48] and in defect models in different species
[38, 50]. BMPs originate from the transforming growth
factor-β family, including at least 18 proteins [29]. BMP-2,
which has been described as an anthelix structure, seems to
possess the highest osteoinductive potential among the
BMPs [25]. In recent years, the regenerative potential of
recombinant human BMP-2 (rhBMP-2) has been demon-
strated in various experimental animal studies, including
sinus floor augmentation, alveolar ridge preservation, bone
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31, 33, 49]. Most recently, the effects of rhBMP-2 on the
osseointegration of titanium implants have also been
investigated in experimental animal studies [14, 26, 33–
37, 45]. Experimental titanium plasma-sprayed hollow
cylinder implants were filled with a solution of rhBMP-2
soaked on an absorbable type-I collagen sponge before
insertion. The histomorphometric analysis revealed a
significantly increased bone regeneration in rhBMP-2-
treated defects compared to controls. Furthermore, the level
of osseointegration, as measured by direct bone-implant
contact, was significantly higher for the rhBMP-2 implants
compared to controls [34]. Recently, biologically active
rhBMP-2 has also been covalently immobilized on metal
surfaces [16, 19–21, 44]. Osseointegration of rhBMP-2-
biocoated plasma spray-coated titanium–alloy cylinders, as
evaluated histomorphometrically 4 weeks after implanta-
tion in the distal femur condylus in a gap healing model in
sheeps, was predominantly characterized by circumferen-
tial bone formation and integration with minimal residual
gaps. In contrast, control specimens generally exhibited a
wide gap surrounding the implant cylinder [18]. The
rationale for BMP immobilization was to avoid ectopic
bone formation by a limited and targeted release of rhBMP-
2 from the implant surface. Recently, treatment of titanium
with chromosulfuric acid (CSA) has been reported to result
in ultrahydrophilic bioadhesive surfaces, which in turn
improves biocoating with rhBMP-2 [19]. However, there
are currently no histological data evaluating osseointegra-
tion of CSA-modified and rhBMP-2-biocoated titanium
implants.
Therefore, the aim of the present study was to investigate
histomorphometrically bone formation to CSA-enhanced
and rhBMP-2-biocoated titanium implants after implanta-
tion in the mandibula and tibia of dogs in comparison to
control titanium implants.
Materials and methods
Animals
Two 3-year-old male mongrel dogs (approximate weight
25 kg) were used in the study. Both animals exhibited a
fully erupted, healthy, permanent dentition. During the
experiment, the dogs were fed ad libitum with soft-food
diet and water. Animal selection, management, and surgery
protocol were approved by the Animal Care and Use
Committee of Belgrade University (ref. no. 2179). The
experimental segment of the study started after an adap-
tation period of 4 weeks.
Study design
The study was performed in two surgical phases. In the first
phase, extraction of the mandibular second, third, and
fourth premolar and first molar (P2–M1) was performed
bilaterally. After 4 months of healing, surgical implantation
of rhBMP-2-biocoated and rhBMP-2-noncoated screw-
typed implants was performed in a submerged healing
procedure during the second phase. Throughout the study
period, oral hygiene procedures were performed three
times a week including tooth and implant brushing.
Radiographs were obtained before and immediately after
tooth extraction as well as immediately after implant
installation. Both animals were killed after a healing period
of 4 weeks.
Implant preparation
RhBMP-2 was prepared as previously described [21]. The
biological activity of soluble rhBMP-2 was assessed with
MC3T3-E1cellsbytheinductionofthedenovosynthesisof
alkaline phosphatase (AP) [43]. The half-activation con-
stants (K0.5) were in the range of 20–75 nM [18]. Twenty-
four screw-type implants (Camlog Screw Line, Wimsheim,
Germany) were manufactured from commercially pure
titanium. The core diameter of the implants was 3.3 mm
andthetotal lengthwas 11mm.Atotal ofsix(n=6)implants
were sand-blasted and acid-etched according to a standar-
dized procedure (Promote, Altatec, Wimsheim, Germany)
(C), while a total of 18 (n=18) implants were surface-
enhanced by a novel procedure with CSA [21]. The
treatment of metals with CSA (CSA–Ti–alloy) [21]l e a d s
to ultrahydrophilic (contact angles 0–10°, no hysteresis)
bioadhesive surfaces [17]. A total of 12 (n=12) surface-
enhanced implants were divided into two subgroups (A and
B) and biocoated with rhBMP-2 [BMP-A: noncovalently
immobilized rhBMP-2 (596 ng/cm
2), BMP-B: covalently
immobilized rhBMP-2 (819 ng/cm
2)] [40]. RhBMP-2
was immobilized by covalent and noncovalent methods on
theseCSA-treatedsurfaces[18,21,40].Inbrief,theimplants
were assigned to the following test and control groups:
BMP-A (n=6), BMP-B (n=6), CSA (n=6), and C (n=6).
To control the produced surface, the following “sibling
method” was employed: Parallel to the preparation of the
above dental implants for in vivo experiments, miniplates
(10×5×1 mm) with identical Promote surfaces were
surface-enhanced with CSA and coated with
125I-rhBMP-
2 under identical conditions as the dental implants. In this
way, the corresponding contact angles, the amount of
immobilized rhBMP-2, and the in vitro biological activity
[6] could be tested before the implants were placed into the
animals. Only those dental implants were released for
implantation, whose sibling miniplates reached the stan-
dard as mentioned above and whose surfaces showed an
intense in vitro bioactivity by fluorescence microscopy [6].
Surgical procedure for both phases
The dogs were anesthetized with 1 mg/kg sodium pento-
barbital. To maintain hydration, both animals received a
constant rate infusion of lactated Ringer’s solution while
being anesthetized. Prophylactic antibiotics were adminis-
trated intraoperatively with a combination of 20,000 IU
218penicillin and 1.0 g streptomycin/10 kg body weight. In the
first surgery, P2–M1 were carefully removed after reflec-
tion of full thickness mucoperiosteal flaps and tooth
separation. After wound closure by means of mattress
sutures, the sites were allowed to heal for 4 months. In the
second surgery, the test and control implants were
randomly allocated to both sides of the mandible (left
and right sides, one implant each) and one implant each to
either the posterior left or right tibia. In brief, bilateral
vestibular incisions were made, and full thickness
mucoperiosteal flaps were elevated to expose the respec-
tive sites for implant placement in the mandible. Surgical
implant sites were prepared bilaterally, at a distance of
10 mm apart, according to the protocol suggested by the
manufacturer. All implants in the mandible were sealed
with cover screws (Camlog, Wimsheim, Germany). After
irrigation, mucoperiosteal flaps were repositioned, and
primary wound closure was achieved with consecutive
polyglycolic acid 5.0 Polyester sutures (Resorba,
Nürnberg, Germany). An area of approximately 15 cm in
length and 4 cm in width was depilated on the respective
side of the tibia using an electric shaver and a razor blade.
After disinfection with polyvidone iodine (Betaisodona,
Mundipharma, Limburg/Lahn, Germany), a skin incision
was made and a flap was elevated to expose the respective
sites of the tibia for implant placement. On the inner-
posterior side of the tibias, implants were inserted at a
distance of 30 mm apart. All titanium implants were
inserted with good primary stability according to a low-
trauma surgical technique under copious irrigation with
sterile 0.9% physiological saline. After implant placement,
the periosteum and fascia were sutured using 3.0 Polyester
sutures (Resorba, Nürnberg, Germany).
Animal killing and retrieval of specimens
The animals were killed (overdose of sodium pentobarbi-
tal, 200 mg/kg i.v.) after 4 weeks. The jaws as well as the
posterior tibias were dissected, and blocks containing the
experimental specimens were obtained. Block sections of
the anterior tibia served as additional control (UC). All
specimens were fixed in 10% neutral buffered formalin
solution for 4–7 days. The specimens were dehydrated
using ascending grades of alcohol and xylol, and infiltrated
and embedded in methylmethacrylate (MMA, Technovit
7200, Heraeus Kulzer, Wehrheim, Germany) for nonde-
calcified sectioning. After 18 to 24 h, the specimens were
completely polymerized. Each implant site was cut in the
mesiodistal direction and along with the long axis of the
implant using a diamond wire saw (Exakt, Apparatebau,
Norderstedt, Germany), resulting in four sections of
approximately 500 μm in thickness [7]. Subsequently, all
specimens were glued with acrylic cement (Technovit 7210
VLC, Heraeus Kulzer, Wehrheim, Germany) to opaque
Plexiglas and ground to a final thickness of approximately
40 μm. All sections were stained with toluidine blue.
Histological and histomorphometric analysis
Histomorphometrical analyses as well as microscopic
observations were performed by one experienced investi-
gator masked to the specific experimental conditions. For
histomorphometrical measurements, images were obtained
using a light microscope (BX50, Olympus, Hamburg,
Germany) at a magnification of 100×, associated with a
video camera (SIS Color View3, Soft imaging System
GmbH, Münster, Germany). Digital images were evaluated
using a software program (SIS analySIS Auto Software
3.2, Soft imaging System GmbH, Münster, Germany). The
percentage of direct contact between mineralized bone and
the titanium surface (bone to implant contact—BIC) was
measured at every thread on both sides of the implant [23].
BIC was subdivided into crestal and apical values (upper
and lower halves of the intraosseous implant length,
respectively). Furthermore, in the tibias, induced bone
density (BD) adjacent to the titanium surfaces was
Fig. 1 Boxplots with outliners for the medians and Q1–Q3 quartiles
of BIC and BD (%) in different groups after 4 weeks of healing with
respective values in the crestal and apical portion of the implant
(BIC) and at a distance of less than and greater than 1 mm adjacent
to the implant surface (BD). Lines below and above box plots min,
max. control c. a BIC mandibula. b BIC tibia. c BD tibia
219measured at distances of <1 and 1 mm by assessing the
ratio of mineralized bone vs bone marrow within the
respective areas [28].
Results
Clinical observations
The postoperative healing was uneventful in both dogs. No
complications such as allergic reactions, abscesses, or
infections were observed throughout the study period.
Histological and histomorphometric analysis
BIC and BD values for each group and respective
anatomical sites (mandible and tibia) are presented in
Fig. 1a–c. In particular, all test and control implants
inserted in the mandible generally exhibited new bone
formation in direct contact with the implant interface. The
formation of organized trabeculas of woven bone,
recognized by osteon formation, could be observed in all
groups. However, new bone formation in direct contact
with the implant interface appeared to be higher in the
BMP groups (Fig. 2a–d). In particular, BIC values
appeared to be highest in the BMP-B group, followed by
BMP-A, CSA, and C groups. No differences in BIC with
respect to crestal and apical values were observed within or
between groups (Fig. 1a).
In comparison to the organized trabeculas of woven
bone noted in the mandible, bone formation in the tibia
seemed to be of a cancellous type, mainly characterized by
tiny trabeculas (Fig. 3a–d). BIC values appeared to be
highest in the BMP-B group, followed by BMP-A, CSA,
and C groups. Again, with respect to crestal and apical BIC
values, no differences were observed within groups
(Fig. 1b). Histomorphometric analysis of BD in the tibia
at a distance of <1 mm revealed obvious differences
between groups. In particular, highest values were noted
for both BMP groups (BMP-A=BMP-B). This was
followed by CSA, also exhibiting higher BD values than
Fig. 2 Histology of representa-
tive titanium implants after
4w e e k so fh e a l i n gi nt h em a n d i -
ble (original magnification ×40).
BIC appeared to be highest for
BMP-B, followed by BMP-A,
CSA, and C. a C. b CSA.
c BMP-A. d BMP-B
220C. No differences between groups were found at a distance
of >1 mm (Fig. 2c).
Discussion
The present histological study was designed to evaluate
bone formation and direct bone apposition to rhBMP-2-
biocoated, CSA surface-enhanced, and C titanium implants
after implantation in the mandible and tibia of dogs. In
particular, rhBMP-2 was immobilized by covalent and
noncovalent methods on CSA surface-enhanced titanium
implants [18, 21, 40]. Within its limits, histomorpho-
metrical analysis of implants inserted in both mandible and
tibia after 4 weeks revealed that BIC values appeared to be
highest in the BMP groups, followed by CSA and C
groups. Furthermore, it was observed that BD as measured
at a distance of <1 mm in the tibia was obviously highest in
the BMP-B group, followed by BMP-A, CSA, and C
groups. However, no differences between groups were
observed at a distance of >1 mm. In this context, it is
important to realize that the present pilot study does not
have the statistical power to rule out the possibility of a
difference between groups. Further experimental studies of
higher power are needed to support equivalence or
superiority [10]. On the other hand, it needs also to be
pointed out that these are the first histological data
evaluating bone formation and apposition on rhBMP-2-
biocoated and CSA surface-enhanced titanium implants in
the mandible and tibia. However, the present findings
corroborate, to a certain extent, previous results observed in
an ectopic bone formation model [40]. Electropolished
titanium miniplates were surface-enhanced by CSA and
coated with a total amount of 150–200 ng rhBMP-2.
Periosteal flaps were prepared from the anterior surface of
the tibias of adult rabbits and wrapped around the titanium
specimens. Additionally, some titanium miniplates were
inserted to which nonimmobilized soluble rhBMP-2 was
added. After 28 days of healing, noncoated specimens
revealed bone formation in 2/12 implants, rhBMP-2-coated
implants in 6/8, and implants with free rhBMP-2 in 8/8
cases. However, in the case of rhBMP-2-coated implants,
Fig. 3 Histology of representa-
tive titanium implants after
4 weeks of healing in the tibia
(original magnification ×10).
BIC and BD appeared to be
highest for BMP-B, followed by
BMP-A, CSA, and C. a C.
b CSA. c BMP-A. d BMP-B
221the induced bone had direct contact to the implant in all
cases. In contrast, titanium miniplates inserted with free
administered rhBMP-2 revealed direct BIC in just six
cases, whereas in two cases, the titanium surface was
separated by a fibrous capsule [40]. The finding that
rhBMP-2 may promote periimplant bone regeneration and
osseointegration of titanium implants is in accordance with
the previous studies [14, 26, 33–37, 45]. In all of these
studies, however, rhBMP-2 was admixed with a carrier
(i.e., collagen, calcium-phosphate cement carrier), acting as
a slow delivery system, for instillation with the implant due
to a rapid diffusion of BMP after implantation in vivo. In
particular, Sigurdsson et al. [33] evaluated rhBMP-2-
(2×0.43 mg/ml in a type-I bovine collagen carrier) induced
bone regeneration and osseointegration in a supraalveolar
periimplant defect model in dogs. At 16 weeks after
healing, bone regeneration (height) was significantly larger
for rhBMP-2 than control defects. However, the large
amount of BMP-induced bone was poorly adapted to the
implant surface. In contrast, the smaller amount of new
bone in the control group seemed to be well adapted [33].
In contrast, Wikesjö et al. [45] reported similar BIC values
16 weeks after implantation of rhBMP-2 (0.4 and 0.75 mg/
ml in a calcium-phosphate cement carrier) or carrier alone
subsequent to a vertical alveolar ridge augmentation
procedure and simultaneous implant installation in dogs.
Furthermore, Howell et al. [14] applied rhBMP-2 using a
collagen sponge carrier to stimulate bone formation in
artificially created defects around endosseous implants in
the canine mandible. Nonresorbable expanded tetrafluoro-
ethylene (e-PTFE) membranes served as controls. Histo-
logical analysis revealed that the addition of rhBMP-2
resulted in a significantly greater amount of new bone area
and BIC after 4 and 12 weeks of healing than e-PTFE.
Although membrane-treated sites were reported to have
less new bone formation after 4 weeks of healing, this
difference seemed to be equalized after 12 weeks [14].
Similar results were also reported by Sykaras et al. [34].
RhBMP-2-induced bone regeneration and osseointegration
was evaluated in mandibular bony defects created within
the hollow chamber of endosseous dental implants in dogs.
Before insertion, hollow chambers were filled with 20 μg
of rhBMP-2 soaked on an absorbable type-I collagen
sponge (0.4 mg/ml). Histological observation revealed
statistically significant higher BIC values in the rhBMP-2
group at 8 and 12 weeks after implantation [34]. There
might be several explanations for the discrepancies noted
in these studies. First of all, it must be emphasized that little
information is available on the interaction between rhBMP-
2 and the individual carriers. Furthermore, the high
concentrations of rhBMP-2 used in these studies (in the
milligram per milliliter range) strongly indicate that an
optimal method is still lacking. In this context, it is
important to point out that BMP-2 has the potency to
induce or modulate apoptosis [24], and that in vivo
application of high doses of BMP-2 may inhibit bone
formation [22, 30]. Furthermore, the results of a recent cell
culture study have shown that the dose-dependent effect of
rhBMP-2 on AP induction in MC3T3-E1 cells plateaus out
into a maximal response at 300–1,000 nM BMP-2 (i.e.,
8–25 μg/ml) [43]. Indeed, the results of the present study
have shown that BIC and BD values seemed to be
ameliorated after application of rhBMP-2 at far lower
concentrations. Furthermore, it must also be noted that the
effects of rhBMP-2 were limited to a range of 1 mm,
outlining that both covalent and noncovalent methods of
immobilization seemed to be stable. This finding may also
be supported by the observation that no differences with
respect to BIC values were observed in crestal and apical
areas of the implant surface in all groups. In accordance, it
might be hypothesized that from a clinical point of view,
both methods of immobilization are suitable to avoid
ectopic bone formation due to a limited and targetedrelease
of rhBMP-2 from the implant surface. However, further
studies are needed to clarify this issue.
Within the limits of the present study, it may be
concluded that rhBMP-2 immobilized by covalent and
noncovalent methods on CSA-treated implant surfaces
seemed to be stable and promoted direct bone apposition in
a concentration-dependent manner.
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